Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development

Clinical Trials

Volumn 7, Issue 2, 2010, Pages 167-173

  Quinlan, Judith ^a   Gaydos, Brenda ^b   MacA, Jeff ^c   Krams, Michael ^d  

^a Cytel Incorporated   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTATION; CHANGE MANAGEMENT; DECISION MAKING; DRUG MANUFACTURE; FOOD AND DRUG ADMINISTRATION; HEALTH SURVEY; PHARMACEUTICS; PRIORITY JOURNAL; QUANTITATIVE STUDY; REVIEW; ARTICLE; CLINICAL TRIAL; DRUG INDUSTRY; HEALTH CARE ORGANIZATION; HUMAN; METHODOLOGY; ORGANIZATION AND MANAGEMENT; RISK ASSESSMENT;

NEW DRUG;

CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; HUMANS; RESEARCH DESIGN; RISK ASSESSMENT; SOCIETIES;

EID: 77953666447     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774510361542     Document Type: Review

References (13)

1. Krams M, Sharma M, Dragalin V, et al. Adaptive approaches in clinical drug development. Opportunities and challenges in design and implementation. Pharm Med 2009; 23: 139-48.
2. Bretz F, Branson M, Burman CF, et al. Adaptivity in drug discovery and development. Drug Dev Rev 2009; 70: 169-90.
3. Gallo P, Chuang-Stein C, Dragalin V, et al. Executive summary of the PhRMA working group on adaptive designs in clinical drug development. J Biopharm Stat 2006; 16: 275-83.
4. Gallo P, Krams M. PhRMA working group on adaptive designs: introduction to the full white paper. Drug Info J 2006; 40: 421-3.
5. Quinlan JA, Krams M. Implementing adaptive designs: logistical and operational considerations. Drug Info J 2006; 40: 437-44.
6. Fardipour P, Littman G, Burns D, et al. Planning and executing response-adaptive learn-phase clinical trials: 1. Theprocess. Drug Info J 2009; 43: 713-23.
7. Gaydos B, Anderson K, Berry DA, et al. Good practices for adaptive clinical trials in pharmaceutical product development. Drug Info J 2009; 43: 539-56.
8. Gallo P. Confidentiality and trial integrity issues for adaptive designs. Drug Info J 2006; 40: 445-50.
9. CHMP. CHMP reflection paper on "Methodological issues in confirmatory clinical trials planned with an adaptive design." Available at: www.emea.europa.eu/pdfs/human/ewp/245902enadopted.pdf. (accessed 20 December 2009).
10. Dragalin V. Designing, monitoring, and modifying an adaptive trial. Am Pharm Outsourc 2008; 9: 12-16.
11. Enas G, Anderson K, Bedding A, et al. Global harmo-nization of standards for adaptive clinical trial designs. Regul Focus 2008;13: 8-17.
12. Chuang-Stein C, Bretz F, Komiyama O, Quinlan J. Interactions with regulatory agencies to enhance the understanding and acceptance of adaptive designs. Regul Focus 2009; 14: 36-42
13. Dick Clark in an interview with the Financial Times 2006. Available at: http://www.ft.com/cms/s/0/e7bde0ee-bb4d-11da-8f5 1-0000779e2340.html?nclick- check=1. (accessed 20 December 2009).